Concept
Cardiovascular Care
9 studies
Cardiovascular care studies test treatments, pathways, and risk management for heart disease and related outcomes.
Cardiology claims move fast; these papers anchor what controlled and observational evidence actually shows.
Studies
9
Findings
7
9 supporting · 0 challenging · 1 qualifying citations
Open tensions
1
Currently
What we know
- Multiple studies in this library examine cardiovascular care with empirical patient or population outcomes rather than opinion alone.
- ITT primary events 17% tele vs 33% control (RRR 50%, P=.06); per-protocol RRR 54% (P=.04); NYHA improved only in tele group; HF hospital stays shorter (median 6.5 vs 10 days).
- Potential prevention remained roughly one quarter to one third of cases and had not declined between cohorts spanning about two decades, motivating public-health action.
- Mortality associated with increasing age, male sex, Black vs white race, prior MI, heart failure, dementia, chronic lung, liver, and renal disease, and metastatic solid tumour; common comorbidities included COPD and diabetes.
- Observationally, each 4 kg/m² BMI related to about 26% higher IHD odds; the causal instrumental-variable OR was about 1.52 (52% higher). Alleles raised BMI by ~0.28 kg/m² each.
Largest unresolved question
Effect sizes and settings differ across cardiovascular care studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Common misconceptions
Cardiovascular Care findings always generalise to every clinic.
These studies are context-bound; designs, populations, and endpoints limit transfer.
Related
Claim ledger
What the evidence shows
Drawn from 9 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
Multiple studies in this library examine cardiovascular care with empirical patient or population outcomes rather than opinion alone.
- Phone telemonitoring after heart-failure flare
- How much dementia could prevention still avert?
- COVID-19 death risk and comorbidities
Study Role Design N Population Outcome Phone telemonitoring after heart-failure flare Supports RCTMOBITEL multicentre RCT; home telemonitoring via mobile phones vs control N=120 · Stopped early at 120 of a planned 240 (eight centres; median age 66); many patients could not operate the phone Adults after acute heart-failure decompensation Cardiovascular death or HF re-hospitalisation over 6 months How much dementia could prevention still avert? Supports CohortRotterdam Study; population attributable risks for modifiable risks across earlier and later cohorts N=7003 · 7,003 in original-cohort analyses; extended cohort analysed separately (n=2,953) Rotterdam Study participants without prevalent dementia Population attributable fraction of dementia from modifiable cardiovascular risks and education COVID-19 death risk and comorbidities Supports CohortFederated US EMR analysis (Jan–May 2020) across 24 organisations N=31461 · Adults with COVID-19 codes or positive tests US adults with COVID-19 in a multi-organisation federated EMR network Mortality associations with Charlson comorbidities and demographics ITT primary events 17% tele vs 33% control (RRR 50%, P=.06); per-protocol RRR 54% (P=.04); NYHA improved only in tele group; HF hospital stays shorter (median 6.5 vs 10 days).
Potential prevention remained roughly one quarter to one third of cases and had not declined between cohorts spanning about two decades, motivating public-health action.
Mortality associated with increasing age, male sex, Black vs white race, prior MI, heart failure, dementia, chronic lung, liver, and renal disease, and metastatic solid tumour; common comorbidities included COPD and diabetes.
Observationally, each 4 kg/m² BMI related to about 26% higher IHD odds; the causal instrumental-variable OR was about 1.52 (52% higher). Alleles raised BMI by ~0.28 kg/m² each.
Each additional 10 g/day olive oil associated with 13% lower major CVD events (HR 0.87) and 16% lower CV mortality (HR 0.84).
In HYVET, frailty did not cancel the stroke and CV benefit of antihypertensive treatment at age 80+.
In 2,656 HYVET participants aged 80+, median frailty index was 0.17. Indapamide±perindopril still cut fatal/non-fatal stroke (HR 0.64) and CV events (HR 0.59); FI×treatment interaction p-values were 0.52, 0.73, and 0.61.
- Phone telemonitoring after heart-failure flare— post-discharge HF telemonitoring RCT ≠ very-elderly hypertension × frailty interaction
Study Role Design N Population Outcome Should very old frail people still get blood-pressure pills? Supports RCTSecondary frailty-index analysis of HYVET, a double-blind placebo-controlled antihypertensive RCT in people aged ≥80. N=2656 · HYVET randomized 3,845; FI calculable in 2,656 with extra QoL data (1,324 placebo; 1,332 active). Hypertensive adults aged 80+ in HYVET (mean age ~83.5; ~61% women). Stroke, cardiovascular events, and total mortality; interaction of treatment with baseline 60-item frailty index. Phone telemonitoring after heart-failure flare Qualifiespost-discharge HF telemonitoring RCT ≠ very-elderly hypertension × frailty interaction RCTMOBITEL multicentre RCT; home telemonitoring via mobile phones vs control N=120 · Stopped early at 120 of a planned 240 (eight centres; median age 66); many patients could not operate the phone Adults after acute heart-failure decompensation Cardiovascular death or HF re-hospitalisation over 6 months
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
Effect sizes and settings differ across cardiovascular care studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Effect sizes and settings differ across cardiovascular care studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
- Phone telemonitoring after heart-failure flare
- How much dementia could prevention still avert?
- COVID-19 death risk and comorbidities
Study Role Design N Population Outcome Phone telemonitoring after heart-failure flare Supports RCTMOBITEL multicentre RCT; home telemonitoring via mobile phones vs control N=120 · Stopped early at 120 of a planned 240 (eight centres; median age 66); many patients could not operate the phone Adults after acute heart-failure decompensation Cardiovascular death or HF re-hospitalisation over 6 months How much dementia could prevention still avert? Supports CohortRotterdam Study; population attributable risks for modifiable risks across earlier and later cohorts N=7003 · 7,003 in original-cohort analyses; extended cohort analysed separately (n=2,953) Rotterdam Study participants without prevalent dementia Population attributable fraction of dementia from modifiable cardiovascular risks and education COVID-19 death risk and comorbidities Supports CohortFederated US EMR analysis (Jan–May 2020) across 24 organisations N=31461 · Adults with COVID-19 codes or positive tests US adults with COVID-19 in a multi-organisation federated EMR network Mortality associations with Charlson comorbidities and demographics
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Cardiovascular Care
- Added a scope qualifier
Phone telemonitoring after heart-failure flare
- Added a supporting study
Should very old frail people still get blood-pressure pills?
New claim
In 2,656 HYVET participants aged 80+, median frailty index was 0.17. Indapamide±perindopril still cut fatal/non-fatal stroke (HR 0.64) and CV events (HR 0.59); FI×treatment interaction p-values were 0.52, 0.73, and 0.61.
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
In 2,656 HYVET participants aged 80+, median frailty index was 0.17. Indapamide±perindopril still cut fatal/non-fatal stroke (HR 0.64) and CV events (HR 0.59); FI×treatment interaction p-values were 0.52, 0.73, and 0.61.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Should very old frail people still get blood-pressure pills?
- Coverage updated · Added a scope qualifier: Phone telemonitoring after heart-failure flare
- Coverage updated · Concept page published
Papers
9 studies in this library bear on Cardiovascular Care, ordered by citations.
- COVID-19 death risk and comorbidities
In 31,461 US adults with COVID-19, older age, male sex, Black race, and several comorbidities including heart disease predicted higher mortality.
- OSA severity and cardiovascular risk
In >10,000 sleep-study patients, higher apnea–hypopnea burden predicted cardiovascular events and death over years of follow-up.
- Should very old frail people still get blood-pressure pills?
In 2,656 HYVET participants aged 80+, frailty did not cancel the benefit of indapamide±perindopril: stroke HR 0.64 and CV-event HR 0.59, with no significant FI×treatment interaction.
- Does higher BMI causally raise heart disease risk?
Genetic instruments for BMI suggest a causal increase in ischemic heart disease risk larger than simple observational estimates.
- Literacy-friendly HF self-care trial
A literacy-sensitive outpatient heart failure education program improved knowledge and self-efficacy but did not clearly cut hospitalizations or quality-of-life scores versus usual care.
- Olive oil intake and CVD risk
Higher olive oil intake tracked lower major CVD events and cardiovascular death in PREDIMED participants.
- How much dementia could prevention still avert?
In Rotterdam cohorts, about one quarter to one third of dementia cases were potentially attributable to modifiable risks—and that share did not shrink over two decades.
- How broadly does smoking raise heart and vessel disease risk?
In a large Australian cohort, current smoking raised risk across nearly all CVD subtypes—especially peripheral arterial disease—and quitting lowered risk.
Show 1 more studiesShow fewer studies
- Phone telemonitoring after heart-failure flare
Home mobile-phone telemonitoring after acute heart-failure decompensation cut primary events and hospital days versus usual care.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
Effect sizes and settings differ across cardiovascular care studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Ask PaperFren about Cardiovascular Care
Study this conceptflashcards and short-answer questions
What is Cardiovascular Care and why do health students study it?
Cardiovascular care studies test treatments, pathways, and risk management for heart disease and related outcomes. Cardiology claims move fast; these papers anchor what controlled and observational evidence actually shows.
Name one limit of the evidence base for Cardiovascular Care in this library.
Single-setting trials, observational designs, or digital-only samples limit causal and external claims.